Look up one drug

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Rosiglitazone Brand(s): Avandia DOSAGE FORM/ STRENGTH: 2 mg, 4 mg, 8 mg tablet For the treatment of type 2 diabetes mellitus in patients with: • Inadequate glycemic control (HbA1c >7%) from ALL other oral antidiabetic agents* funded through one of the Ontario Drug Benefit Programs, in monotherapy or in combination OR • Where ALL other oral antidiabetic agents are inappropriate due to contraindications or intolerance AND • The patient has refused or is not able to take insulin AND • There is no known contraindication to rosiglitazone * Oral antidiabetics include the following agents;  glyburide  metformin  gliclazide (Diamicron, Diamicron MR)  sitagliptin (Januvia)  saxagliptin (Onglyza)  repaglinide (GlucoNorm)  pioglitazone (Actos) Note: A trial with acarbose is not a mandatory requirement. Note: It is not necessary for patients to have tried the following oral antidiabetic agents that are currently not funded by the OPDP for the purposes of obtaining rosiglitazone:  glimepiride (Amaryl)  nateglinide (Starlix) Duration of Approval: 5 years Renewals will be considered where patients have benefited and continue to benefit from rosiglitazone treatment as demonstrated by recent HbA1c levels ≤7% while on treatment with rosiglitazone AND in those who continue to have no known contraindication(s) to rosiglitazone. Duration of Approval: 5 years 36  EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 36, record 17, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Rosiglitazone Brand(s): Avandia DOSAGE FORM/ STRENGTH: 2 mg, 4 mg, 8 mg tablet For the treatment of type 2 diabetes mellitus in patients with: • Inadequate glycemic control (HbA1c >7%) from ALL other oral antidiabetic agents* funded through one of the Ontario Drug Benefit (ODB) Programs, in monotherapy or in combination OR • Where ALL other oral antidiabetic agents are inappropriate due to contraindications or intolerance AND • The patient has refused or is not able to take insulin AND • There is no known contraindication to rosiglitazone. * Oral antidiabetics that need to be tried prior to consideration of rosiglitazone include the following agents currently reimbursed through the Ontario Public Drug Programs;  glyburide  metformin  gliclazide (Diamicron, Diamicron MR)  sitagliptin (Januvia)  repaglinide (GlucoNorm)  pioglitazone (Actos)  saxagliptin (Onglyza) Note: A trial with acarbose is not a mandatory requirement. Note: It is not necessary for patients to have tried the following oral antidiabetic agents that are currently not funded by the Ontario Public Drug Programs for the purposes of obtaining rosiglitazone: Standard Approval Duration: 5 years 472 Rosiglitazone Brand(s): Avandia DOSAGE FORM/ STRENGTH: 1 mg, 4 mg, 8 mg tablet Renewals will be considered where patients have benefited and continue to benefit from rosiglitazone treatment as demonstrated by achieving adequate glycemic control. This is shown by a recent HbA1c levels ≤7% while on treatment with rosiglitazone AND in who continue to have no known contraindication(s) to rosiglitazone. Standard Approval Duration: 5 years Palliative Care Medications NOTE: Specific products used to treat ODB-eligible patients undergoing palliative care are reimbursed under the Ontario Public Drug Programs, as Limited use benefits on the ODB formulary or through the Facilitated Access process. Under this process, a select group of participating physicians and nurse practitioners are exempt from obtaining approval under EAP on a case-by-case basis. This assumes that the prescriber has met the qualifications set by their professional associations who administer the enrollment of their members. The prescriber’s license number with their regulatory body must appear on the prescription, for purposes of verification. Palliative Care medication claims to be reimbursed by the ODB program must be prescribed in accordance with the following patient eligibility criteria: “This patient has a progressive, life-limiting illness and has chosen outpatient palliative treatment. Life expectancy of one year is applied to request durations. In order to participate in the Facilitated Access to Palliative Care Drugs process, these prescribers must be registered with their professional association as meeting the qualifications for pCFA enrollement.. For physicians this is by the Ontario Medical Association (“OMA”) and must meet pre-defined criteria the OMA sets. For nurse practitioners, this may be the NPAO or the Nurse practitioners Association of Ontario (NPAO) or the RNAO, th Registered Nurse Association of Ontario. To facilitate the reimbursement process at the pharmacy, these prescribers are asked to indicate either, “Palliative” or “P.C.F.A.” on the prescription. Prescribers who are not registered through this process must obtain approval through the Exceptional Access Program. A prescriber must provide the details of the patient’s diagnosis, current clinical status, and life expectancy. For further information regarding the list of physicians and/or the criteria physicians require to be included on the list, please contact the Ontario Medical Association: (416) 340-2234, or via email. The following products can be reimbursed for the management of patients receiving palliative care through the Telephone Request Service. Note that many Palliative Care drugs have tranoptsitioned to the ODB formulary for funding under Limited Use and do not require EAP authorization. treat ODB- 473  EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 472, record 311, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Avandia · DIN 02241113 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2007-01-02 Health Canada: Cancelled post market since 2020-12-01 · brand AVANDIA · ATC A10BG02 ROSIGLITAZONE · form Tablet · route Oral · ingredients ROSIGLITAZONE (ROSIGLITAZONE MALEATE) 4 MG · company Glaxosmithkline inc · schedule Prescription

DIN 02241113: Avandia Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 682002017; group id 753; item number 1847; lccId None; manufacturer id GSK Source form: Tab; strength: 4mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02241113 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64717

Interchangeable products

Rosiglitazone · DIN 02403374 · $1.9197

Shortage status: discontinued (2020-12-01, reported by GLAXOSMITHKLINE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02241113

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2020-12-01 — choose a marketed DIN from the same-category list.